Price History
Feb 9, 2026 — Mar 24, 2026Investment Snapshot
- Trading 35% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 15.6% — good return on equity
- Revenue declining 5% annually
Alkermes plc - Ordinary Shares (ALKS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $4.6 billion . Key value metrics: P/E ratio 16.2, P/B ratio 2.54, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Alkermes plc - Ordinary Shares — Fundamental Analysis Summary
Alkermes plc - Ordinary Shares (ALKS) is currently trading 35% above its Graham Number of $20.48, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 16.2x.
On financial health, ALKS shows a moderate Piotroski F-Score of 4/9, and solid return on equity of 15.6% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.16.
StockPik's composite Value Score for ALKS is 84/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ALKS reports a high gross margin of 85.5% (sector average: 33.5%) and a strong operating margin of 20.5%.
ALKS shows revenue declining at 5% year-over-year, with earnings declining at 34%.